ArticleResearch square2026
Prioritizing Therapeutic Targets for Interstitial Lung Disease: A Causal Mediation Analysis.
Justin Oldham, Philip Molyneaux, Manoj Maddali, Chad Newton, John Kim, Sam Konkol, Janelle Pugashetti, Gabrielle Liu, Gillian Goobie, Ayodeji Adegunsoye and 25 more
Abstract readPreprint
In one paragraphArticle in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
35 authors.
Justin OldhamUniversity of Michigan.
Manoj MaddaliPiedmont Healthcare.
Sam KonkolUniversity of Virginia.
Janelle PugashettiUniversity of Michigan.
Gabrielle LiuUniversity of California at Davis.
Gillian GoobieUniversity of British Columbia.
Ayodeji AdegunsoyeUniversity of Chicago.
Drew BornsteinUniversity of Michigan.
Susan MurrayUniversity of Michigan.
Gauri SainiUniversity of Nottingham.
Iain StewartImperial College London.
Gisli JenkinsNational Heart and Lung Institute, Imperial College.
Mary StrekUniversity of Chicago.
Angela LinderholmUniversity of California at Davis.
William FahyGlaxoSmithKline (United Kingdom).
Christopher RyersonUniversity of British Columbia.
Kevin FlahertyUniversity of Michigan.
Madathilparambil SureshUniversity of Michigan-Ann Arbor.
Anna-Maria Hoffmann-VoldOslo University Hospital.
Imre NothUniversity of Virginia School of Medicine.
Funding
POSTDOCTORAL TRAINING IN MEDICAL INFORMATION SCIENCEST15LM007033 · NLM · STANFORD UNIVERSITY · PI SYLVIA KATINA PLEVRITIS · 1985 to 2026
$25.5MPulmonary Fibrosis and Telomerase DysfunctionR01HL093096 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI GARCIA, CHRISTINE KIM · 2009 to 2024
$6.9MLung Remodeling Mediated by Telomere Dysfunction in Alveolar Type II CellsR01HL139897 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Paul j WOLTERS · 2018 to 2026
$5.5MProteomic Profiling of Idiopathic Pulmonary Fibrosis Progression TrajectoryR01HL169166 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Justin M Oldham · 2023 to 2026
$2.7MPrognostic Biomarker Development in Progressive Fibrosing Interstitial Lung DiseaseR01HL166290 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Justin M Oldham · 2024 to 2026
$2.2MImmune crosstalk in lung injury and fibrosisR35HL176572 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Bethany B. Moore · 2025 to 2026
$2.1M1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUG3HL145266 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARTINEZ, FERNANDO J, NOTH, IMRE · 2019 to 2019
$977kMolecular Markers of Idiopathic Pulmonary Fibrosis ProgressionK23HL148498 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI NEWTON, CHAD ALAN · 2020 to 2024
$891kRole of polyunsaturated fatty acids in pulmonary fibrosisK23HL150301 · NHLBI · UNIVERSITY OF VIRGINIA · PI KIM, JOHN S · 2021 to 2025
$858kImproving Pulmonary Fibrosis Classification with Genomics Informed Phenotypic ClustersK23HL146942 · NHLBI · UNIVERSITY OF CHICAGO · PI ADEGUNSOYE, AYODEJI · 2020 to 2024
$810kA Multi-Dimensional Signature to Predict Treatment Failure in Patients with Connective Tissue Disease-Associated Interstitial Lung DiseaseK23HL171871 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Janelle Vu Pugashetti · 2025 to 2026
$392kNHLBI NIH HHS K23 HL146942NHLBI NIH HHS K23 HL148498NHLBI NIH HHS K23 HL150301NHLBI NIH HHS K23 HL171871NHLBI NIH HHS L30 HL181822NHLBI NIH HHS R01 HL093096NHLBI NIH HHS R01 HL139897NHLBI NIH HHS R01 HL166290NHLBI NIH HHS R01 HL169166NHLBI NIH HHS R35 HL176572NHLBI NIH HHS UG3 HL145266NLM NIH HHS T15 LM007033
6 · The paper itselfAbstract
Progressive interstitial lung disease (ILD) leads to declining lung function and death. New therapies to treat ILD are urgently needed. Here we performed a secondary analysis of proteomic data from ten ILD cohorts across the United States, Canada, and United Kingdom. Causal mediation analysis was used to estimate the effect of plasma proteins previously linked to organ fibrosis in mechanistic studies (exposure) on survival (outcome) through lung function decline (mediator). Of 102 proteins tested in a discovery cohort (n = 1963), 47 were mediated by declining lung function. Of these 47 proteins, 7 showed sustained mediation in an independent validation cohort (n = 1172). Proteins with the strongest mediated effect were amphiregulin and integrin beta six. Sensitivity analysis showed that results were robust to unmeasured confounding. Here we provide epidemiological evidence implicating seven proteins as potentially causal of progressive ILD. These findings build upon mechanistic studies showing a causal link between these proteins and organ fibrosis, supporting their prioritization for therapeutic consideration.
Indexed as
BiomarkerInterstitial Lung DiseaseMediationProgressive Pulmonary FibrosisProteomics
Identifiers
PMID41674845
PMCPMC12889817
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390